drugset / Trial / NCT02857166
Study of JS001 in Participants With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with advanced solid tumors.
Timeline
- Start
- 2016-03
- Primary completion
- 2017-09
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | Toripalimab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Toripalimab | Monoclonal antibody | 10 mg/kg | — |